Find News

Filter articles

Showing 1 to 10 of 1712 results

Alnylam faces declaratory relief claim over SPCs


Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates requested by biotech company Silence Therapeutics.

CJEU clarifies jurisdiction rules in ‘Merck’ trademark battle

EU, Germany, UK19-10-2017

Europe’s highest court has found that in parallel lawsuits dealing with an identical trademark, the first court must take priority over the second—but not in all cases.

Amneal and Impax merge to become ‘fifth largest’ generics company

US19-10-2017Mergers & acquisitions

Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Broad and DuPont yield CRISPR licensing deal in agriculture


The Broad Institute of Harvard and MIT has signed a patent licensing deal with DuPont Pioneer to provide CRISPR/Cas9 technology to agricultural researchers and producers.

Sanofi leads the way for gene therapy patents: report


CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.

Allergan deal with tribe could kill off IPR: Bryson


A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.

AIPPI 2017: Eli Lilly counsel discusses ‘convoluted’ Amgen v Sanofi ruling


A patent counsel at Eli Lilly discussed a recent dispute pitting Amgen against Sanofi and Regeneron, saying an appeals court ruling was convoluted.

House of Lords hears evidence on life sciences and Brexit

EU, UK17-10-2017

The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.

Tribe defends Allergan deal in letter to senators


The Saint Regis Mohawk Tribe has launched a fierce defence of its patent licensing deal with Allergan, giving the Senate Judiciary Committee six main reasons which justify the agreement.

Orexigen defeats Actavis in weight loss pill battle


US pharmaceutical company Orexigen Therapeutics has won a patent infringement case against Actavis Laboratories after suing the company over weight loss pill Contrave (naltrexone HCl/bupropion HCl extended release).

Showing 1 to 10 of 1712 results